Summary:
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care
Qualified Participants Must:
• Have a diagnosis of Lupus
Qualified Participants May Receive:
All study related procedures and office visits with a board certified Rheumatologist at no cost.
Patients will be paid $50 per completed visit.